Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

ITK inhibitors may effectively treat alopecia areata.

This paper highlights the emerging trend of treating androgenic alopecia with botulinum toxin, despite insufficient scientific evidence supporting its effectiveness.

This review discusses the molecular mechanisms and clinical applications of thymosin β4, highlighting its potential benefits for inflammation, wound healing, tumor metastasis, and other medical conditions but reports no new experimental results.

In this retrospective study, tofacitinib showed promise as a treatment for alopecia areata, with 46.5% of patients experiencing a very good response and minimal adverse effects, suggesting it could be a primary option for moderate to severe cases.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

This study found that the EtOAc extract of Tridax procumbens aerial parts significantly inhibited rat paw edema and COX enzyme activity, suggesting its potential anti-inflammatory properties.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

In this study, intralesional triamcinolone acetonide injections were associated with halting the progression of frontal fibrosing alopecia in female patients and showed minimal adverse effects, but the efficacy as sole therapy remains unclear pending further trials.

This study found that there was no significant difference in hair regrowth between clobetasol and bimatoprost for scalp alopecia areata over 12 weeks, but bimatoprost had fewer side effects and prompted earlier, more pigmented hair regrowth.

This review discusses the emerging roles of transit-amplifying cells in tissue regeneration and cancer formation, highlighting their significance beyond a mere transitional state in hair follicles and the hematopoietic system.

This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.

Abatacept may help some people with alopecia areata regrow hair.

The researchers reported that intralesional botulinum toxin A effectively alleviated pain associated with cutaneous leiomyomas in a patient with hereditary leiomyomatosis and renal cell cancer syndrome, with repeated treatments every three months maintaining pain relief over 1.5 years.

This case report describes a 43-year-old male with alopecia totalis who successfully regrew all his hair after six months of treatment with tofacitinib, with no relapse at one year.

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

In this study, photobiomodulation therapy applied twice weekly for 12 weeks significantly improved hair regrowth and quality of life in alopecia areata patients, with no noted side effects.

In this study, researchers found that both the EU-TIRADS and Bethesda systems exhibited high specificity but suboptimal sensitivity for predicting thyroid nodule malignancy in patients who underwent surgery, with Bethesda system showing particularly high specificity in this postoperative population.

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

This study estimates that adding baricitinib to a commercial formulary for treating severe alopecia areata would slightly increase the budget by $1,383,345 over five years, with minimal impact per member per month.

This letter discusses a previous study on tofacitinib for alopecia areata, questioning its statistical analysis and suggesting that steroids may have influenced results, but it reports no new clinical findings.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

In this pediatric retrospective study, tofacitinib (a Janus kinase inhibitor) improved the severity of alopecia and quality of life more effectively than traditional treatment methods, with significant reductions in alopecia severity score and dermatology life quality index over 16 weeks.

This study found that longer-chain cationic surfactants like BTMC provided superior hair conditioning by reducing combing forces, but did not reverse oxidative hair damage, emphasizing the role of molecular structure in surfactant performance.

Tanshinone IIA helps protect skin tissue from low oxygen damage by boosting certain cell markers.

In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.

In this study, intralesional triamcinolone acetonide 10 mg/mL combined with topical betamethasone dipropionate 0.05% lotion was found to be more effective for treating alopecia areata than either treatment alone.